Twelve mutations make tau form disease structures

In the study, researchers show that twelve targeted modifications to the tau protein are sufficient to produce, in the laboratory, the exact paired helical filaments found in patient brain tissue. They call this set of modifications PAD12. The changes mimic phosphate groups that attach to the protein in diseased brains, a process known as phosphorylation.

Under normal conditions, tau stabilises the internal transport rails (microtubules) of nerve cells. In Alzheimer’s disease and more than twenty related conditions, collectively called tauopathies, it loses this function. Instead, it begins to aggregate into characteristic filament structures. Cryo-electron microscopy has revealed that these structures differ between diseases, suggesting that the precise shape of the aggregates may determine which disease a person develops.

A lab model that matches brain tissue

Until now, no laboratory model could reliably replicate these disease-specific structures. Earlier approaches used fragments of the protein or chemical additives that altered its shape. PAD12 works with the complete, unmodified protein and produces structures that match those found in patient brain tissue.

This matters for drug development. A reliable model makes it possible to test candidate compounds against structures that genuinely resemble the disease. Researchers can now screen substances that interfere with filament formation or break down existing aggregates.

Implications for tauopathy research

The next step is to determine whether PAD12 can also reproduce the structures specific to individual tauopathies. Some brain diseases have a distinct tau architecture that sets them apart. If researchers can replicate those in the lab as well, it opens the door to disease-specific drug development. This model represents a meaningful step toward more targeted research into brain diseases in which tau plays a central role.

Read the original article